Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

AUGUST 16, 2022

Even giant pharma companies with large internal production capabilities are leaning on outsourcing to meet market demand for huge numbers of injectables, including high-value biologics and Covid-19 vaccines, according to a GlobalData analysis. Why do large and mega-cap sponsors outsource?

Gene Therapy 162

Gene Therapy Packaging Packaging Contract Packaging 162

XTalks

OCTOBER 4, 2023

Heather McDonald: My previous role at Bayer was a global-level role with a specific focus on cell and gene therapies. In addition, AstraZeneca just announced a major acquisition of Pfizer’s cell and gene therapy portfolio. How is the shift toward value-based healthcare affecting drug pricing and reimbursement?

Marketing 105

Marketing Development Drugs Gene Therapy 105

XTalks

JANUARY 4, 2023

With a handful of significant gene therapy approvals in 2022, the cell and gene therapy space continues to rapidly expand, and hence we can expect more ground-breaking gene therapy approvals in the coming year, particularly for rare diseases. Read the full article here: 4 Life Sciences Trends for 2023.

Life Science 52

Life Science Gene Therapy Gene Pharma Companies 52

Drug Discovery World

JANUARY 25, 2024

Japan-based pharma company Kyowa Kirin has successfully completed the acquisition of gene therapy developer Orchard Therapeutics. Libmeldy is known as OTL-200 in the US, where it is currently an investigational drug under Priority Review by the Food and Drug Administration (FDA).

Gene Therapy 52

Gene Therapy Gene Pharma Companies Drugs 52

XTalks

FEBRUARY 16, 2022

In this episode, Ayesha discussed the NHS’s recommendation of Libmeldy, a gene therapy for the treatment of the rare disease MLD, which is officially the world’s most expensive drug with a list price of almost $4 million USD. Libmeldy was initially rejected by the drug price watchdog NICE in England over its exorbitant price.

Life Science 52

Life Science Gene Therapy Drugs Pharma Companies 52

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Cell and gene therapies. There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. .

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 92

Genetics Drugs Genome Project Biobanking 92

Drug Discovery World

DECEMBER 14, 2023

With leading academic institutions and significant recent investment, Glasgow is shaping up to be an important centre for drug discovery and development in the UK. Discoveries in these areas will identify new treatments which will become the cancer drugs of the future.” DDW’s Diana Spencer explores the city’s unique ecosystem.

Drugs 75

Drugs Life Science Research Scientist 75

XTalks

MARCH 28, 2024

Italy-based drugmaker Italfarmaco has won US Food and Drug Administration (FDA) approval for its oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. The global incidence of DMD is approximately one in every 3,500 to 6,000 male births.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

XTalks

APRIL 16, 2024

Lady Gaga’s continuing partnership with Pfizer has yielded another video ad for the company’s migraine drug Nurtec ODT (Rimegepant). Watch the ad here: Lady Gaga’s Journey, The Next Chapter The ad opens with Gaga saying “Nothing dims my light like a migraine” and goes on to reveal how she found relief with migraine drug Nurtec ODT.

Drugs 52

Drugs Pharma Companies Doctors Doctor 52

pharmaphorum

NOVEMBER 30, 2020

Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. This is particularly pertinent in rare diseases, as a number of gene therapy products use viral delivery methods to deliver the transgene to target organs.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

Drug Discovery World

FEBRUARY 10, 2023

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. For instance, Swedish biotech Lokon Pharma worked with the Testa Center for nine weeks on a project to scale up its manufacturing process for its gene therapy candidate.

Life Science 52

Life Science Drugs Gene Therapy Manufacturing 52

pharmaphorum

DECEMBER 14, 2022

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. In addition, two team members are taking on new roles at the company, with Glen Webster named EVP of global operations and Jennifer White named global head of growth. New CEO joins UBC.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

pharmaphorum

OCTOBER 12, 2022

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies. The post AstraZeneca builds its AI capabilities again with Illumina tie-up appeared first on.

Genome 64

Genome Genomics DNA Drugs 64

pharmaphorum

SEPTEMBER 3, 2020

King’s Cross is also home to Google’s DeepMind artificial intelligence company, which has already been involved in life sciences projects such as using the technology to predict acute kidney injury. The tech giant NVIDIA will also send a team of engineers to the building to explore ways of collaborating to discover new drugs.

Life Science 106

Life Science Engineer Scientist Pharma Companies 106

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

Drug Discovery World

AUGUST 4, 2023

With so many exciting novel treatments emerging from the labs, biotechs and pharma companies need to understand the potential unknowns as well as the known considerations if they are to optimise their impact in the real world. Other challenges involve talent gaps, particularly now that cell and gene therapy manufacturing is maturing.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Pharmaceutical Technology

JULY 6, 2022

This period of hype saw companies going public earlier, which could explain why we may see some companies being merged or bought out, says Jason Foster, CEO of Ori Biotech, a private cell and gene therapy manufacturing company. The bear market has also impacted venture capital investment into private pharma companies.

Marketing 324

Marketing Gene Therapy Manufacturing Pharma Companies 324

Drug Discovery World

DECEMBER 27, 2023

You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. These are just some of the words that come to mind when talking about not just the drug discovery sector, but the lives of those working in and around it. He speaks about this drug discovery journey here. Developing. Listen here.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. The shortages have been partly blamed on the off-label prescribing of the drugs for weight loss.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Masato Ohbuchi, Senior Researcher, Astellas. Who Should Attend?

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. The post BioArctic left in the cold as AbbVie abandons Parkinson’s pact appeared first on.

Antibody 89

Antibody Protein Gene Therapy Pharma Companies 89

Drug Discovery World

SEPTEMBER 28, 2022

Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery. . Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

Camargo

MARCH 9, 2021

The FDA revealed that pharma companies are not forthcoming when they publicly disclose the reasons behind a refuse-to-file (RTF) letter from the Agency. In fact, when they do disclose their existence, companies disclosed only 5% of the reasons for the RTF.

Development 146

Development Manufacturing Drugs Production 146

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

pharmaphorum

NOVEMBER 23, 2021

The DISC is the biggest investment AZ has ever made, and has been hailed by the pharma company’s chief executive Pascal Soriot as the centrepiece of what he believes could one day become a biotech hub to rival Boston and San Francisco in the US.

Gene Editing 105

Gene Editing Life Science Pharma Companies Clinical Trials 105

Drug Discovery World

APRIL 27, 2023

Dr Mansley also comments that the multitude of biotech and pharma companies in the Greater Boston region means that people regularly move organisations. She said: “When one of our customers leaves a company and moves to a new one up the street, they often get in touch with us, which helps us grow new business.

Life Science 52

Life Science Drugs Research Gene Splicing 52

pharmaphorum

JANUARY 6, 2021

Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, as the company prepares for the launch of a phase 3 trial in spring. A host of other pharma companies including Gilead, Novo Nordisk, Merck & Co are also developing potential NASH drugs.

Gene Silencing 52

Gene Silencing Regulation Pharma Companies Doctors 52

Drug Channels

FEBRUARY 6, 2024

Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

Pharmacy 40

Pharmacy Gene Therapy Pharma Companies Production 40

pharmaphorum

NOVEMBER 22, 2022

Francis, who is currently CEO of gene therapy specialist Purespring Therapeutics and cardiovascular drug developer company Forcefield Therapeutics, is due to take the top job at Teva on 1 January, and will serve as the pharma company’s president. Richard Francis.

Sales 59

Sales Gene Therapy Pharma Companies Gene 59

pharmaphorum

SEPTEMBER 22, 2022

Envision’s Rachel Shemer, along with TwoLabs’ Kimberly Cash and Angus Bromley, examine key elements of a successful drug launch. What physicians need from post-pandemic pharma comms. Gene therapies for prevalent diseases in Europe. Moving forward the evolution of digital maturity in pharma.

Gene Therapy 52

Gene Therapy Marketing Gene Sales 52

XTalks

OCTOBER 22, 2020

Pharmaceutical development of novel drugs is a complex and tedious process. The information shared between different multidisciplinary teams is critical to reducing the cost and ultimately accelerating the path of bringing a drug to market.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

Research 125

Research Gene Editing Gene Development 125

Pharmaceutical Technology

JUNE 14, 2023

A GlobalData report which analyzes trends in new drug approvals [i] shows that small molecule approvals have now been surpassed (in 2022) by biologics. Biologics form 51% of the current global drugs pipeline (highest stage of development as pipeline) according to GlobalData’s Drugs database (as of February 7, 2023).

Contract Packaging 130

Contract Packaging Packaging Packaging Development 130

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Unlike conventional cancer drugs Vitravki can be used in tumours with this mutation regardless of whether they are in the body.

Marketing 78

Marketing Gene Silencing Gene Drugs 78